Please use this identifier to cite or link to this item:
|Title:||Influence of CYP3A5 and SLCO1B1 polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients|
David M. Burger
University of New South Wales (UNSW) Australia
Faculty of Medicine, Khon Kaen University
The HIV Netherlands Australia Thailand Research Collaboration
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Radboud University Nijmegen Medical Centre
Chiang Mai University
|Keywords:||Biochemistry, Genetics and Molecular Biology|
|Citation:||Pharmacogenomics. Vol.20, No.7 (2019), 517-527|
|Abstract:||© 2019 Future Medicine Ltd. Aim: To evaluate the influence of genetic polymorphisms on plasma trough concentrations of atazanavir (ATV) and ritonavir (RTV). Patients & methods: The concentration-to-dose ratios were compared between different genotype groups of CYP3A5, ABCB1, SLCO1B1 and NR1I2 in 490 patients. Multiple regression analysis was used to examine the association between genetic and clinical factors and log-transformed concentration-to-dose ratio of ATV and RTV. Results: Higher concentrations of ATV and RTV were significantly associated with CYP3A5 6986 GG and SLCO1B1 521 TC or CC. Female patients had significantly higher ATV plasma concentration than male patients. Conclusion: Genetic polymorphisms and gender are factors affecting the variability of ATV and RTV concentrations in the Thai population. Thus, genetic testing is worth considering when atazanavir + low dose ritonavir is prescribed.|
|Appears in Collections:||Scopus 2019|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.